6617 Stock Overview
Gongwin Biopharm Holdings Co., Ltd., a clinical-stage biopharmaceutical company, develops anticancer drugs.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Gongwin Biopharm Holdings Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$190.50 |
| 52 Week High | NT$309.50 |
| 52 Week Low | NT$167.00 |
| Beta | 0.84 |
| 1 Month Change | -0.78% |
| 3 Month Change | -2.56% |
| 1 Year Change | -35.75% |
| 3 Year Change | 13.06% |
| 5 Year Change | 228.45% |
| Change since IPO | 108.88% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6617 | TW Biotechs | TW Market | |
|---|---|---|---|
| 7D | 5.2% | 2.6% | 1.4% |
| 1Y | -35.8% | -21.4% | 30.6% |
Return vs Industry: 6617 underperformed the TW Biotechs industry which returned -21.4% over the past year.
Return vs Market: 6617 underperformed the TW Market which returned 30.6% over the past year.
Price Volatility
| 6617 volatility | |
|---|---|
| 6617 Average Weekly Movement | 4.2% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in TW Market | 8.7% |
| 10% least volatile stocks in TW Market | 2.3% |
Stable Share Price: 6617 has not had significant price volatility in the past 3 months.
Volatility Over Time: 6617's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | n/a | Yuan Lin Mao | www.gongwinbiopharm.com |
Gongwin Biopharm Holdings Co., Ltd., a clinical-stage biopharmaceutical company, develops anticancer drugs. It is developing PTS302, which has completed Phase III clinical trials for the treatment of lung cancer; PTS100, which is in Phase II clinical trials for the treatment of liver cancer; PTS-02 for the treatment of adenoid cystic carcinoma; and PTS500 for the treatment of malignant pleural effusion. The company was founded in 2014 and is based in Taipei, Taiwan.
Gongwin Biopharm Holdings Co., Ltd. Fundamentals Summary
| 6617 fundamental statistics | |
|---|---|
| Market cap | NT$21.59b |
| Earnings (TTM) | -NT$101.17m |
| Revenue (TTM) | NT$18.92m |
1,141x
P/S Ratio-213.4x
P/E RatioIs 6617 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6617 income statement (TTM) | |
|---|---|
| Revenue | NT$18.92m |
| Cost of Revenue | NT$7.72m |
| Gross Profit | NT$11.20m |
| Other Expenses | NT$112.38m |
| Earnings | -NT$101.17m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.89 |
| Gross Margin | 59.21% |
| Net Profit Margin | -534.89% |
| Debt/Equity Ratio | 5.7% |
How did 6617 perform over the long term?
See historical performance and comparison